This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in
Use the Pep Pal reconstitution calculator to lock in draw volume
I want to change the stigma
Formulated with clinically proven ingredients used in effective concentrations Transparency about product formulations
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II/III trials
This includes reviewing your medical history, current medications, lab work, and specific objectives, whether those involve injury recovery, body composition improvement, or general wellness
